SALBUTAMOL
Information current as at: 1 August 2025
Submission Details
- Brand name:
-
- Ventolin®
- Pharmaceutical company:
- GlaxoSmithKline Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Asthma; Chronic obstructive pulmonary disease (COPD)
- PBAC Submission type:
- New listing (Minor)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents - November 2019
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2019 PBAC meeting
-
Opportunity for consumer comment: - Open 28/08/2019 and close 09/10/2019 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2019
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Exception applied
-
Lodgement of required documentation: - 15/05/2020
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 19/05/2020
-
Status:
- Finalised
-
Government processes: - Commenced on 09/06/2020
-
Medicine listed on the PBS: - 01/08/2020 (see PBS schedule)
Case ID: a091
Page last updated: 30 June 2025